125 related articles for article (PubMed ID: 17310536)
1. DCs for HIV vaccine?
Nat Rev Microbiol; 2007 Mar; 5(3):172. PubMed ID: 17310536
[No Abstract] [Full Text] [Related]
2. In vivo targeting of protein antigens to dendritic cells using anti-DEC-205 single chain antibody improves HIV Gag specific CD4
Ngu LN; Nji NN; Ambada GE; Sagnia B; Sake CN; Tchadji JC; Njambe Priso GD; Lissom A; Tchouangueu TF; Manga Tebit D; Waffo AB; Park CG; Steinman RM; Überla K; Nchinda GW
Immun Inflamm Dis; 2019 Jun; 7(2):55-67. PubMed ID: 28474788
[TBL] [Abstract][Full Text] [Related]
3. Preparation of clinical-grade recombinant canarypox-human immunodeficiency virus vaccine-loaded human dendritic cells.
Marovich MA; Mascola JR; Eller MA; Louder MK; Caudrelier PA; El-Habib R; Ratto-Kim S; Cox JH; Currier JR; Levine BL; June CH; Bernstein WB; Robb ML; Schuler-Thurner B; Steinman RM; Birx DL; Schlesinger-Frankel S
J Infect Dis; 2002 Nov; 186(9):1242-52. PubMed ID: 12402193
[TBL] [Abstract][Full Text] [Related]
4. Poly(I:C) Potentiates T Cell Immunity to a Dendritic Cell Targeted HIV-Multiepitope Vaccine.
Apostólico JS; Lunardelli VAS; Yamamoto MM; Cunha-Neto E; Boscardin SB; Rosa DS
Front Immunol; 2019; 10():843. PubMed ID: 31105693
[TBL] [Abstract][Full Text] [Related]
5. Intensified and protective CD4+ T cell immunity in mice with anti-dendritic cell HIV gag fusion antibody vaccine.
Trumpfheller C; Finke JS; López CB; Moran TM; Moltedo B; Soares H; Huang Y; Schlesinger SJ; Park CG; Nussenzweig MC; Granelli-Piperno A; Steinman RM
J Exp Med; 2006 Mar; 203(3):607-17. PubMed ID: 16505141
[TBL] [Abstract][Full Text] [Related]
6. Improving defences at the portal of HIV entry: mucosal and innate immunity.
Shattock RJ; Haynes BF; Pulendran B; Flores J; Esparza J;
PLoS Med; 2008 Apr; 5(4):e81. PubMed ID: 18384232
[TBL] [Abstract][Full Text] [Related]
7. Low-dose penile SIVmac251 exposure of rhesus macaques infected with adenovirus type 5 (Ad5) and then immunized with a replication-defective Ad5-based SIV gag/pol/nef vaccine recapitulates the results of the phase IIb step trial of a similar HIV-1 vaccine.
Qureshi H; Ma ZM; Huang Y; Hodge G; Thomas MA; DiPasquale J; DeSilva V; Fritts L; Bett AJ; Casimiro DR; Shiver JW; Robert-Guroff M; Robertson MN; McChesney MB; Gilbert PB; Miller CJ
J Virol; 2012 Feb; 86(4):2239-50. PubMed ID: 22156519
[TBL] [Abstract][Full Text] [Related]
8. CD40L-containing virus-like particle as a candidate HIV-1 vaccine targeting dendritic cells.
Franco D; Liu W; Gardiner DF; Hahn BH; Ho DD
J Acquir Immune Defic Syndr; 2011 Apr; 56(5):393-400. PubMed ID: 21239998
[TBL] [Abstract][Full Text] [Related]
9. Incorporation of CD40 ligand into SHIV virus-like particles (VLP) enhances SHIV-VLP-induced dendritic cell activation and boosts immune responses against HIV.
Zhang R; Zhang S; Li M; Chen C; Yao Q
Vaccine; 2010 Jul; 28(31):5114-27. PubMed ID: 20471443
[TBL] [Abstract][Full Text] [Related]
10. Vaccination with a fusion protein that introduces HIV-1 gag antigen into a multitrimer CD40L construct results in enhanced CD8+ T cell responses and protection from viral challenge by vaccinia-gag.
Gupta S; Termini JM; Raffa FN; Williams CA; Kornbluth RS; Stone GW
J Virol; 2014 Feb; 88(3):1492-501. PubMed ID: 24227853
[TBL] [Abstract][Full Text] [Related]
11. Systems analysis of MVA-C induced immune response reveals its significance as a vaccine candidate against HIV/AIDS of clade C.
Gómez CE; Perdiguero B; Jiménez V; Filali-Mouhim A; Ghneim K; Haddad EK; Quakkelaar ED; Delaloye J; Harari A; Roger T; Duhen T; Sékaly RP; Melief CJ; Calandra T; Sallusto F; Lanzavecchia A; Wagner R; Pantaleo G; Esteban M
PLoS One; 2012; 7(4):e35485. PubMed ID: 22536391
[TBL] [Abstract][Full Text] [Related]
12. Development and Evaluation of an Ebola Virus Glycoprotein Mucin-Like Domain Replacement System as a New Dendritic Cell-Targeting Vaccine Approach against HIV-1.
Ao Z; Wang L; Azizi H; Olukitibi TA; Kobinger G; Yao X
J Virol; 2021 Jul; 95(15):e0236820. PubMed ID: 34011553
[TBL] [Abstract][Full Text] [Related]
13. HIV vaccine and pathogenesis update. The 2005 HIV Keystone symposium.
Hardy G
GMHC Treat Issues; 2005; 19(5-6):9-14. PubMed ID: 16193578
[No Abstract] [Full Text] [Related]
14. Human dendritic cell interactions with whole recombinant yeast: implications for HIV-1 vaccine development.
Barron MA; Blyveis N; Pan SC; Wilson CC
J Clin Immunol; 2006 May; 26(3):251-64. PubMed ID: 16783464
[TBL] [Abstract][Full Text] [Related]
15. HIV Gag protein conjugated to a Toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8+ T cell responses in nonhuman primates.
Wille-Reece U; Flynn BJ; Loré K; Koup RA; Kedl RM; Mattapallil JJ; Weiss WR; Roederer M; Seder RA
Proc Natl Acad Sci U S A; 2005 Oct; 102(42):15190-4. PubMed ID: 16219698
[TBL] [Abstract][Full Text] [Related]
16. Characterization of immune responses elicited in mice by intranasal co-immunization with HIV-1 Tat, gp140 DeltaV2Env and/or SIV Gag proteins and the nontoxicogenic heat-labile Escherichia coli enterotoxin.
Caputo A; Brocca-Cofano E; Castaldello A; Voltan R; Gavioli R; Srivastava IK; Barnett SW; Cafaro A; Ensoli B
Vaccine; 2008 Feb; 26(9):1214-27. PubMed ID: 18243435
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity of attenuated vesicular stomatitis virus vectors expressing HIV type 1 Env and SIV Gag proteins: comparison of intranasal and intramuscular vaccination routes.
Egan MA; Chong SY; Rose NF; Megati S; Lopez KJ; Schadeck EB; Johnson JE; Masood A; Piacente P; Druilhet RE; Barras PW; Hasselschwert DL; Reilly P; Mishkin EM; Montefiori DC; Lewis MG; Clarke DK; Hendry RM; Marx PA; Eldridge JH; Udem SA; Israel ZR; Rose JK
AIDS Res Hum Retroviruses; 2004 Sep; 20(9):989-1004. PubMed ID: 15585086
[TBL] [Abstract][Full Text] [Related]
18. Immunization with HIV-1 Gag protein conjugated to a TLR7/8 agonist results in the generation of HIV-1 Gag-specific Th1 and CD8+ T cell responses.
Wille-Reece U; Wu CY; Flynn BJ; Kedl RM; Seder RA
J Immunol; 2005 Jun; 174(12):7676-83. PubMed ID: 15944268
[TBL] [Abstract][Full Text] [Related]
19. Cross-Reactive Potential of HIV-1 Subtype C-Infected Indian Individuals Against Multiple HIV-1 Potential T Cell Epitope Gag Variants.
Negi N; Vajpayee M; Singh R; Sharma A; Murugavel KG; Ranga U; Thakar M; Sreenivas V; Das BK
Viral Immunol; 2016 Dec; 29(10):572-582. PubMed ID: 27875663
[TBL] [Abstract][Full Text] [Related]
20. An immunological comparison between lipidated and non-lipidated multivalent HIV-1 peptides representing Gp120 and Gag hypervariable regions.
Ghunaim H; Kumar A; Torres J; Diaz-Mitoma F; Azizi A
Vaccine; 2011 Aug; 29(35):5950-8. PubMed ID: 21718739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
